The impacts of pricing and reimbursement policies on access to cell and gene therapies across Europe

To address the ethical imperative of improving access equality for CGT in Europe, further policy reforms are proposed including concurrent HTA, early benefit assessment, and incorporation of additional elements of value in HTA evaluations, alongside current initiatives to increase cross-border collaboration.